A 52-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group, flexible-adaptive, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease (LIBRA)

Principal Investigator

Thomas Harrington

Enrollment Status

Open

Clinical Trial ID

Institutional Protocol # 20250031

Clinical Trial Summary

A 52-week, multicenter, randomized, double-blind, placebocontrolled,
parallel-group, flexible-adaptive, Phase 3 study
to evaluate the efficacy and safety of rilzabrutinib in
participants aged 10 to 65 years with sickle-cell disease
(LIBRA)

Phase

Phase III

Funding Agency/Sponsor

Industrial

Disease

Classical Hematology

Contact Information

Phone Number 305-243-2647